雍禾医疗在2024年实现营收18.05亿元，同比增长1.5%，EBITDA盈利1.41亿元，业绩显著改善。公司自2022年起进入自我调整变革期，去销售化、去包装化，重塑商业模式。董事长张玉表示，这些举措是为了企业未来长远发展。报告期内，雍禾医疗暂停快速扩店战略，优化9家低效院部，植发医疗机构从51家缩减至42家，史云逊独立门店也从13家减至8家。通过优化门店网络布局和资源重新配置，公司提升了运营...
Source Link雍禾医疗在2024年实现营收18.05亿元，同比增长1.5%，EBITDA盈利1.41亿元，业绩显著改善。公司自2022年起进入自我调整变革期，去销售化、去包装化，重塑商业模式。董事长张玉表示，这些举措是为了企业未来长远发展。报告期内，雍禾医疗暂停快速扩店战略，优化9家低效院部，植发医疗机构从51家缩减至42家，史云逊独立门店也从13家减至8家。通过优化门店网络布局和资源重新配置，公司提升了运营...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.